Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

National Joint-Replacement Registry Unveils First Data Report

This article was originally published in The Gray Sheet

Executive Summary

The mean age of knee replacement patients is slightly younger than those with hip replacements, and more females than males have joints replaced. Those are among the findings in the inaugural report of the American Joint Replacement Registry, which aspires to become a national clearinghouse for data on U.S. hip and knee procedures.

You may also be interested in...



CDRH Details Path Forward For National Post-Market Surveillance System

The device center released an updated plan for post-market surveillance reforms, featuring a planning board that will establish a governing structure for the new system, as well as implementation dates for various post-market projects.

Metal-On-Metal Hips Get Failing Grade In New Registry Analysis

Devices were linked to a notably higher five-year revision rate compared to metal-on-polyethylene or ceramic-on-ceramic hips in an analysis of more than 400,000 implants. Recalled J&J/DePuy ASR devices were not included in the analysis.

Can Organovo Leverage Its Solid Phase II Data In MASH?

Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT033503

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel